KIF11 and breast cancer: Our results evidence that thiadiazole-based Eg5 inhibitors, 2 and 41, appear to negatively modulate proliferation, invasiveness and migration of cancer cells, affecting also the angiogenesis process and the remodeling of the extracellular matrix, thus representing a new promising drug strategy to control breast cancer.